Mouse IgG (H&L) Antibody Rhodamine Conjugated

• Catalog Number: orb347616
• Category: Antibodies
• Description: Mouse IgG (H&L) antibody (TRITC)
• Species/Host: Sheep
• Clonality: Polyclonal
• Tested applications: FC, FLISA, IF
• Reactivity: Mouse
• Isotype: IgG
• Immunogen: Mouse IgG whole molecule
• Concentration: 2.0 mg/mL
• Dilution range: FLISA: 1:10,000 - 1:50,000, FC: 1:500 - 1:2,500, IF: 1:1,000 - 1:5,000
• Form/Appearance: Lyophilized
• Purity: This product was prepared from monospecific antiserum by immunoaffinity chromatography using Mouse IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Sheep Serum, Mouse IgG and Mouse Serum.
• Conjugation: TRITC
• Storage: Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
• Buffer/Preservatives: 0.01% (w/v) Sodium Azide
• Alternative names: sheep anti-Mouse IgG rhodamine Conjugated Antibody
• Note: For research use only
• Application notes: This product is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.
• Expiration Date: 12 months from date of receipt.

Characterization of HeLa (FXN-EGFP) stable cell lines. (D) Determination of transgenic fragment integration site by FISH. Rhodamine-labeled RP11-265B8 was hybridized onto metaphase chromosomes (DAPI stained) of HeLa (left) and HeLa (FXN-EGFP) (right) cells. Three hybridization signals (yellow arrows) corresponded to the endogenous FXN gene. The presence of one additional brighter signal (orange arrow) establishes the presence of a single integration site containing multiple copies of the FXN-EGFP transgene.